VTRS Stock Price, News and Analysis
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up one-third of Viatris' total sales. The remaining sales are derived from its portfolio of legacy products, including Lipitor, Norvasc, Lyrica, and Viagra.
Market Cap: $20,261,142,840.96
Industry: PHARMACEUTICAL PREPARATIONS
Track VTRS stock with real-time alerts and market analysis
Current Price: $17.85
Viatris Inc.
$17.85
+2.18%+$0.38
Major market announcement affects tech stocks across all sectors
Earnings report shows significant growth in quarterly revenue
Regulatory changes impact industry outlook for upcoming quarter